| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J1448 | Trilaciclib | Cosela | 1mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | No | 2021 | Sep 27, 2021 | In Use | ||
| J9110 | Cytarabine | Cytarabine | 500 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 1998 | Jan 1, 1994 | Dec 31, 2010 | No Longer Used | |
| C9237 | Lanreotide Acetate | Somatuline Depot | 1 mg | Hormonal Therapy | Somatostatin Analog | No | 2007 | Jan 1, 2008 | In Use | |||
| J9090 | Cyclophosphamide | Cyclophosphamide | 500 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1959 | Jan 1, 1994 | Dec 31, 2010 | No Longer Used | |
| C9476 | Daratumumab | Darzalex | 10 mg | Immunotherapy | Monoclonal Antibody | CD38 | No | 2015 | Jul 1, 2016 | In Use | ||
| Q5158 | Denosumab-bnht | Bomyntra, Conexxence | 1mg | Immunotherapy | Monoclonal Antibody | RANKL | No | 2025 | Sep 8, 2025 | In Use | ||
| Q5161 | Denosumab-kyqq | Ankelso/Bosaya | 1mg | Immunotherapy | Monoclonal Antibody | RANKL | No | 2025 | Mar 18, 2026 | In Use | ||
| S2107 | Immunotherapy - non specific | Adoptive immunotherapy (ie development of specific anti-tumor reactivity) | NA | Immunotherapy | No | Apr 1, 2002 | In Use | |||||
| J9291 | Mitomycin | Mitosol | 40 mg | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | No | 1981 | Jan 1, 1989 | Dec 31, 2010 | No Longer Used | |
| J1950 | Leuprolide Acetate | Eligard, Lupron Depot, Viadur, Lupron | 3.75 mg | Hormonal Therapy | GnRH Agonist | No | 1989 | Jan 1, 1997 | In Use | |||
| J9217 | Leuprolide Acetate | Eligard, Lupron Depot, Viadur, Lupron | 7.5 mg | Hormonal Therapy | GnRH Agonist | No | 1989 | Jan 1, 1997 | In Use | |||
| J9206 | Irinotecan | Camptosar | 20 mg | Chemotherapy | Topoisomerase I Inhibitor | Campothecin Analogs | No | 1996 | Jan 1, 1998 | In Use | ||
| C9098 | Ciltacabtagene autoleucel | CARVYKTI | up to 100 million | Immunotherapy | CAR-T | No | 2022 | Mar 25, 2022 | Sep 27, 2022 | No Longer Used | ||
| J9160 | Denileukin Diftitox | Ontak | 300 mcg | Immunotherapy | Cytokine | Interleukin-2 | No | 1999 | Jan 1, 2001 | In Use | ||
| C9421 | Cyclophosphamide | Cyclophosphamide lyophilized | 100 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1959 | Jan 1, 2004 | Dec 31, 2005 | No Longer Used | |
| J9282 | Mitomycin Intravesical Instillation | Zusduri | 1mg | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | No | 2025 | Jan 1, 2026 | In Use | ||
| C9064 | Mitomycin pyelocalyceal instillation | Jelmyto | 1mg | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/Mitomycin | No | 2020 | Oct 1, 2020 | Jan 1, 2021 | No Longer Used | |
| J3590 | Immunotherapy - non specific | Unclassified biologics | NA | Immunotherapy | No | Jan 1, 2003 | In Use | |||||
| C9280 | Eribulin mesylate | Halaven | 1 mg | Chemotherapy | Antimitotic Agent | Furopyrans | No | 2010 | Apr 1, 2011 | Dec 31, 2011 | No Longer Used | |
| J9261 | Nelarabine | Arranon | 50 mg | Chemotherapy | Antimetabolite | Purine Analog | No | 2005 | Jan 1, 2007 | In Use | ||
| J9213 | Interferon Alfa-2a | Roeferon- A | 3 million units | Immunotherapy | Cytokine | Interferon | No | 2002 | Jan 1, 2009 | In Use | ||
| J9216 | Interferon Gamma-1b | Actimmune | 3 million units | Immunotherapy | Cytokine | Interferon | No | 1999 | Jan 1, 2009 | In Use | ||
| C9173 | Filgrastim-txid (nypozi) | Nypozi | 1 mcg | Ancillary Therapy | Immunostimulant | Colony-Stimulating Factor | No | 2024 | Dec 17, 2024 | Jul 9, 2025 | In Use | |
| J9021 | Asparaginase Erwinia Chrysanthemi (recombinant)-rywn | Rylaze | 0.1mg | Chemotherapy | Miscellaneous Agent | Enzyme | No | 2021 | Jan 26, 2022 | In Use | ||
| J2353 | octreotide | sandostatin LAR | 1 mg | Hormonal Therapy | Somatostatin Analog | No | 1998 | Jan 1, 2004 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home